[HTML][HTML] Nivolumab in combination with platinum‐based doublet chemotherapy for first-line treatment of advanced non–small-cell lung cancer
NA Rizvi, MD Hellmann, JR Brahmer… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
NA Rizvi, MD Hellmann, JR Brahmer, RA Juergens, H Borghaei, S Gettinger, LQ Chow…
Journal of Clinical Oncology, 2016•ncbi.nlm.nih.govPurpose Nivolumab, a fully human immunoglobulin G4 programmed death-1 immune
checkpoint inhibitor antibody, has demonstrated improved survival in previously treated
patients with advanced non–small-cell lung cancer (NSCLC). CheckMate 012, a phase I,
multicohort study, was conducted to explore the safety and efficacy of nivolumab as
monotherapy or combined with current standard therapies in first-line advanced NSCLC.
Here, we report results for nivolumab plus platinum-based doublet chemotherapy (PT-DC).
checkpoint inhibitor antibody, has demonstrated improved survival in previously treated
patients with advanced non–small-cell lung cancer (NSCLC). CheckMate 012, a phase I,
multicohort study, was conducted to explore the safety and efficacy of nivolumab as
monotherapy or combined with current standard therapies in first-line advanced NSCLC.
Here, we report results for nivolumab plus platinum-based doublet chemotherapy (PT-DC).
Abstract
Purpose
Nivolumab, a fully human immunoglobulin G4 programmed death-1 immune checkpoint inhibitor antibody, has demonstrated improved survival in previously treated patients with advanced non–small-cell lung cancer (NSCLC). CheckMate 012, a phase I, multicohort study, was conducted to explore the safety and efficacy of nivolumab as monotherapy or combined with current standard therapies in first-line advanced NSCLC. Here, we report results for nivolumab plus platinum-based doublet chemotherapy (PT-DC).
ncbi.nlm.nih.gov